

Endospot's Abstract submission:

Company name: Endospot

Website: <https://www.linkedin.com/company/endospot/posts/?feedView=all>

CSO and Co-founder name: Salit Tzaban, PhD

CATEGORY: Biotech/Pharma

SESSION: Mind the Gap, Empowering Women's Health Through Data and Innovation

- Executive Summary / Investment Rational + Core technology

Endospot is developing a novel, local, targeted, sustained-release system for Endometriosis, a chronic inflammatory disease affecting 10% of reproductive-age women globally (200 million). Characterized by estrogen-responsive lesions of uterine-like cells outside the uterus, Endometriosis causes significant pain, infertility, and depression. Current effective treatments are limited to hormonal therapies, including estrogen suppression which induces menopause, bone loss, and depression.

Endospot's sustained-release system delivers an effective treatment directly to peritoneal lesions, minimizing systemic exposure and thus avoiding the severe side effects associated with these hormonal interventions. In-vitro studies demonstrate a 10-week drug release, and in-vivo studies confirm effective peritoneal retention. Backed by the IIA, and an experienced management team, Endospot aims to disrupt the rapidly growing \$7.8 billion endometriosis market.

- Product Profile/Pipeline

Our lead product, in preclinical development, is a sustained-release formulation for treating Endometriosis lesions in the peritoneum. In-vitro studies show a 90-day drug release, and in-vivo studies confirm peritoneal retention. Next, we aim to demonstrate efficacy in animal models. Future applications include other localized therapies for endometriosis and adenomyosis. We are actively seeking collaborations and partnerships to accelerate clinical translation.

- Business Strategy

Our business model centers on a reimbursement strategy, targeting approximately \$9,000 per annum, consistent with established endometriosis therapies. This pricing reflects the product's clinical advantages and the substantial healthcare cost savings derived from reduced complications and improved fertility outcomes, thereby securing a competitive position within the \$7.8 billion market. The societal value in women's improved quality of life is immense.

- What's Next?

Building on the successful animal studies, we are now focused on securing our pre-seed round of investment. This funding will enable us to optimize the drug delivery system, validate our manufacturing process, conduct 2-month pharmacokinetic studies, and demonstrate efficacy in endometriosis models. Endospot's system also enables us to expand our pipeline to address additional therapeutic areas.